"
Team:Goettingen/project overview/therapeutics
From 2014.igem.org
m |
m |
||
| Line 12: | Line 12: | ||
<div class="proLP"> | <div class="proLP"> | ||
<h3>Project</h3> | <h3>Project</h3> | ||
| + | |||
| + | |||
<ul> | <ul> | ||
| - | <li | + | <li>Background |
| - | + | <ul> | |
| - | + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview"><b>The global burden of fungal infections</b></a></li> | |
| - | + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/fungal_infections">Fungal infections</a></li> | |
| - | + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/current_tools">Current diagnostic tools</a></li> | |
| - | + | </ul> | |
</li> | </li> | ||
<li><a href="https://2014.igem.org/Team:Goettingen/project_overview/project">Our project!</a></li> | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/project">Our project!</a></li> | ||
<li><a href="https://2014.igem.org/Team:Goettingen/project_overview/perspectives">Further perspectives</a> | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/perspectives">Further perspectives</a> | ||
| - | + | <ul> | |
| - | + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/diganosis">Diagnosis</a></li> | |
| - | + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/therapeutics">Therapeutics</a></li> | |
| - | + | </ul> | |
</li> | </li> | ||
| + | |||
| + | |||
| + | |||
| + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/project_drylab">Dry lab</a></li> | ||
| + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/project_wetlab">Wet lab</a></li> | ||
| + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/project_gallery">Gallery</a></li> | ||
| + | <li><a href="https://2014.igem.org/Team:Goettingen/project_overview/project_biobrick">BioBrick</a></li> | ||
</ul> | </ul> | ||
| + | |||
</div> | </div> | ||
<!-- end of left column--> | <!-- end of left column--> | ||
| Line 33: | Line 43: | ||
<!-- right column--> | <!-- right column--> | ||
<div class="proRP" id="rpart1"> | <div class="proRP" id="rpart1"> | ||
| - | <div id="goenext"><a href="https://2014.igem.org/Team:Goettingen/project_overview/diganosis"><img src='https://static.igem.org/mediawiki/2014/3/32/Goettingen2014-previous.png' width='50px'></a> 7/ | + | <div id="goenext"><a href="https://2014.igem.org/Team:Goettingen/project_overview/diganosis"><img src='https://static.igem.org/mediawiki/2014/3/32/Goettingen2014-previous.png' width='50px'></a> 7/11</div><br /> |
<h1 >Further perspectives</h1> | <h1 >Further perspectives</h1> | ||
<h2 id="global_burden">Therapeutics</h2> <br /> | <h2 id="global_burden">Therapeutics</h2> <br /> | ||
Revision as of 08:43, 15 September 2014
Project
7/11Further perspectives
Therapeutics
Our peptides can also be attached to an antimycotic or opsonizing moiety and act as a therapeutic tool. Again, if the specificity of the peptides is high enough at the species level, it can help to reduce the toxicity issues related to broad-spectrum antimycotics. Regarding opsonizing moieties (such as immune tags or complement ligands), they may help the weakened immune system to attack the fungal cells. An interesting option to explore would be to attach the constant region of human IgG3 immunoglobulins, which can elicit the response of macrophages and neutophils antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity.
It's important to mention that because most patients suffering from invasive mycoses are immunocompromised patients, the eventual application of peptides as therapeutic tools has to be concomitant with immunostimulant therapy, preferably by activating the celular response.
